HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA
- Wednesday, April 27, 2022, 7:21
- PR Newswire
- Add a comment
PLYMOUTH MEETING, Pa., April 27, 2022 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the initiation of…
About the Author
admin has written 20652 stories on this site.